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Abstract
Vaccines have made a major contribution to public health, including the eradication of one deadly
disease, small pox, and the near eradication of another, poliomyelitis.Through the introduction of
new vaccines, such as those against rotavirus and pneumococcal diseases, and with further
improvements in coverage, vaccination can significantly contribute to the achievement of the
health-related United Nations Millennium Development Goals.The Global Immunization Vision and
Strategy (GIVS) was developed by WHO and UNICEF as a framework for strengthening national
immunization programmes and protect as many people as possible against more diseases by
expanding the reach of immunization, including new vaccines, to every eligible person.This paper
briefly reviews global progress and challenges with respect to public vaccination programmes.
The most striking recent achievement has been that of reduction of global measles mortality from
an estimated 750,000 deaths in 2000 down to 197,000 in 2007.Global vaccination coverage trends
continued to be positive.In 2007 most regions reached more than 80% of their target populations
with three doses of DPT containing vaccines. However, the coverage remains well short of the
2010 goal on 90% coverage, particularly in the WHO region of Africa (estimated coverage 74%),
and South-East Asia, (estimated coverage 69%). Elements that have contributed to the gain in
immunization coverage include national multi-year planning, district-level planning and monitoring,
re-establishment of outreach services and the establishment of national budget lines for
immunization services strengthening.
Open AccessIntroduction
Vaccination has made enormous contributions to public
health, including the eradication of one dreaded disease,
small pox, and elimination of poliomyelitis from all but
a handful of countries. It is estimated that between two
and three million child deaths are averted annually
through vaccination against diphtheria, tetanus, pertussis
and measles and many more future deaths averted in
older groups (e.g. 600,000 future deaths prevented annu-
ally through hepatitis B vaccination). However,
vaccine-preventable diseases are still responsible for
about 25% of the 10 million deaths occurring annually
among children under five years of age [1]. This is partly
related to the fact that an increasing number of infectious
diseases can now be classified as vaccine-preventable.
With the availability of new vaccines, such as those
against rotavirus and pneumococcal diseases, and further
improvements in vaccination coverage, a much larger pro-
portion of children can now be protected against a
broader range of infectious diseases. Thus vaccines have
the potential to make a significant contribution to the
achievement of the health-related United Nations
Millennium Development Goals (MDG), especially
MDG4 [2] that calls for a two third reduction in the
under-five mortality rate by 2015 compared to 1990 lev-
els. However, if the trend in mortality reduction observed
between 1990 and 2005 continues, the goal will not be
achieved [3]. The cost of such a failure would be close to
40 million children deaths.
In 2005, the 58th World Health Assembly, recognizing
the role that vaccines and immunization can play in
reducing under-five mortality, welcomed the Global
Immunization Vision and Strategy (GIVS) 2006–2015
developed by WHO and UNICEF as a framework for
strengthening national immunization programmes [4,5].
Its goal is to protect as many people as possible against
more diseases by expanding the reach of immunization to
every eligible person and ensuring that immunization is
high on every health agenda. The strategy aims to
increase, or at least sustain, very high levels of vaccine cov-
erage, not just for infants but for all age groups, introduce
new vaccines and link immunization with the delivery of
other health interventions. This strategy was drawn up
against a background of increasing demand for vaccines,
rapid progress in developing new vaccines and technolo-
gies, continuing health-sector development, increasing
vulnerability to pandemics and other health emergencies
and more potential opportunities for partnerships.
The purpose of this paper is to briefly review global
progress and challenges with respect to public vaccination
programmes.
Progress
Success of measles mortality reduction efforts
In 2003, the World Health Assembly urged full imple-
mentation of the WHO–UNICEF strategic plan for
measles mortality reduction 2001–2005 [6], and, at the
end of 2005, the major public health goal of reducing
global measles mortality by 50% compared with the 1999
level had been surpassed, with a reduction of 60% [7]. In
2005 the World Health Assembly endorsed a revised goal
to reduce global measles deaths by 90% by 2010 (or earli-
er) compared with 2000 as one of the GIVS goals [4].
Global mortality due to measles was reduced by 74%
from an estimated 750,000 deaths in 2000 to 197,000 in
2007 [8]. The largest percentage reduction in estimated
measles mortality during this period occurred in the
Eastern Mediterranean (90%) and African regions (89%),
accounting for 79% of the global reduction in measles
mortality. Immunization coverage estimates produced
annually by WHO and UNICEF, based on official data
reported by member states and other published data,
showed that in 2007, global coverage with the scheduled
dose of a measles-containing vaccine reached 82%,
increasing from 72% in 2000 [9,10]. The decrease in
measles mortality was the result of both improved routine
coverage and the implementation of mass vaccination
campaigns. These public health accomplishments helped
to prevent nearly 11 million measles deaths between 2000
and 2007, with vaccination campaigns in which more
than 578 million children aged nine months to 15 years
were vaccinated against measles between 2000 and 2007
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Remaining challenges include the need to: develop and implement strategies for reaching the
difficult to reach; support evidence-based decisions to prioritize new vaccines for introduction;
strengthening immunization systems to deliver new vaccines; expand vaccination to include older
age groups; scale up vaccine preventable disease surveillance; improve quality of immunization
coverage monitoring and use the data to improve programme performance;and explore financing
options for reaching the GIVS goals, particularly in lower-middle income countries.
Although introduction of new vaccines is important,this should not be at the expense of sustaining
existing immunization activities. Instead the introduction of new vaccine introduction should be
viewed as an opportunity to strengthen immunization systems, increase vaccine coverage and
reduce inequities of access to immunization services.in 47 high-priority countries accounting for 3.6 million of
these deaths averted. [8] They were made possible by the
enormous efforts made by the national governments of
the targeted priority countries with the highest disease bur-
den and the concentrated focus of immunization partners
on the most effective strategies to control measles rapidly,
supported by predictable financing of the programme. 
Though there has been tremendous success in reducing
measles mortality, deficiencies in routine immunization
coverage are threatening to offset these gains with out-
breaks occurring in regions with low routine
immunization coverage e.g. in Democratic Republic of
Congo, Nigeria, Tanzania and Uganda [8]. This also sug-
gests that the achievements are still fragile.
All countries have implemented a measles mortality
reduction strategy, except India. India’s failure to imple-
ment a strategy would mean that the region may not
achieve the 90% mortality reduction goal, thus also affect-
ing the achievement of the global measles mortality
reduction goal [8].
Progress with routine immunization
Less striking than the success with measles mortality reduc-
tion, but equally important, have been overall
improvements in routine immunization coverage since
2000. These have been most marked in lowest-income
countries, and particularly in sub-Saharan Africa; other
regions, apart from South-East Asia, have continued to
sustain high levels of immunization coverage. In 2007, out
of the estimated 129 million annual surviving infants, a
record 105 million children under one year of age were vac-
cinated worldwide with three doses of diphtheria, tetanus
and pertussis (DTP3) vaccine, and the number of unvacci-
nated children decreased to 24.1 million (11.5 million of
which in South East Asia and 7.3 million in Africa) com-
pared with 33.6 million in 2000 [11]. An estimated 86% of
the unimmunized children live in countries eligible for
funding from the GAVI Alliance and 75% live in just 10
countries in Africa and Asia. These countries include India
with close to 10 million unimmunized children, Nigeria,
China, Indonesia, as well as Bangladesh, the Democratic
Republic of the Congo, Ethiopia, Niger, Pakistan and
Uganda. This is due to the large number of children born
in these countries and/or low vaccination coverage. 
Trends related to global vaccination coverage (as meas-
ured by estimates of delivery of DTP3) continued to be
positive in 2007, as shown in Figure 1 with most regions
sustaining estimated levels of coverage in excess of 80%.
The African region reached a record high vaccination
coverage level of 74%, while estimates for South-East Asia
indicate coverage increasing to 69% yet far away from the
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Figure 1 - Global immunization 1980-2007, DTP3 coverage by WHO region.
Source WHO/UNICEF coverage estimates 1980-2007,August 2008, 193 WHO Member States.80% mark [11]. In a few countries, however, interruption
in immunization services resulted in an actual decline. A
total of 117 (61%) countries reached 90% or more DTP3
coverage in 2007 while 156 (81%) reached a DTP3 cover-
age of 80% or more (Figure 2) [11]. It must be noted,
however, that little progress has been achieved towards all
countries ensuring at least 80% vaccination coverage in
every district or equivalent administrative unit (i.e. one of
the GIVS goals based on equity) and only 44 of the devel-
oping countries (28%) report DTP3 coverage ≥ 80% in all
districts (Figure 3). Indeed, focusing only on average cov-
erage at global or country levels may hide variability
among countries and within countries among districts.
Reaching unreached children remains one of the major
challenges for many developing countries.
Elements that are believed to have contributed to the gain
in immunization coverage include national multi-year
planning, district-level planning and monitoring, and the
establishment of national budget lines, funded with
domestic and external resources, including those provid-
ed by the GAVI for immunization services strengthening.
As a result, routine immunization coverage, seemingly in
stagnation since the early 1990s, now shows an encourag-
ing rising trend, particularly in several countries of
sub-Saharan Africa.
The district planning and monitoring approach promoted
by WHO is based on five key strategies that were initially
repackaged in western Africa into a single strategy, which
has since rapidly gained acceptance globally as the “reach-
ing every district” (RED) strategy. As an example, with this
strategy, vaccination coverage of children in Ethiopia with
a third dose of DTP vaccine improved in 14 of the worst
performing districts, from an average of 35% in 2002 to
71% in 2005. An evaluation of the RED strategy in nine
countries in the region concluded that outreach services
had contributed to increased coverage in districts where
the strategy was implemented. However, lack of adequate
transport facilities remained a limitation to sustaining
outreach services [12]. The strategy has now been imple-
mented to various degrees in 53 developing countries,
mostly in Africa and south and south-east Asia [13].
The strategy of child health days, led by UNICEF, has also
helped to promote routine immunization. Consistent
BMC International Health and Human Rights 2009, 9(Suppl 1):S2 http://www.biomedcentral.com/1472-698X/9/S1/S2
Page 4 of 11
(page number not for citation purposes)
Figure 2 - Immunization coverage with DTP3 vaccines in infants, 2007.
Source:WHO/UNICEF coverage estimates 1980-2007,August 2008, 193 WHO Member States.The boundaries and names
shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the
World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or
concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for
which there may not yet be full agreement. WHO 2008.All rights reserved.with the emphasis of the GIVS on linking immunization
with other health interventions, child health days are reg-
ular events designed to deliver an integrated package of
preventive services such as immunization, vitamin A sup-
plementation, deworming, growth monitoring and
distribution of insecticide-treated bed nets. Of the 25 pri-
ority countries conducting measles supplementary
immunization activities in 2006, 20 (80%) integrated at
least one other child-survival intervention with measles.
For example, in 2006 approximately 21 million insecti-
cide-treated bednets were distributed during measles
campaigns [14]. Child health days which became routine
in many African countries, have achieved high coverage
and have been shown to reduce inequalities in access to
basic health services. They are usually conducted twice a
year and the integrated package that they offer is defined
according to epidemiological needs and local circum-
stances. Preliminary analysis of experience so far in
Ethiopia, Uganda and the United Republic of Tanzania
shows that child health days have helped to deliver mul-
tiple interventions effectively (including immunization),
to improve routine immunization coverage, and to reduce
operational costs per child reached. In contrast to other
health programmes, successful implementation of immu-
nization programmes in Africa has resulted in high rates
of vaccination coverage in most countries. 
Vaccination weeks to promote immunization coverage
using new and existing vaccines are regularly organized in
the Region of the Americas and the European Region.
Endorsed by all Member States in the Region of the
Americas in 2003, vaccination weeks have already reached
more than 200 million children and adults in that Region,
especially in difficult-to-reach populations, isolated com-
munities and towns with low immunization coverage
[15]. During the second European Immunization Week in
April 2007, 25 Member States in the European Region
were involved, underlining the importance of immuniza-
tion through workshops, debates, training courses,
exhibitions and media events [16]. 
New and underused vaccines
The 2003 State of the World’s Vaccines and Immunization
has emphasized the inequity in access to new vaccines
that increased over the last decades as new life-saving vac-
cines became available at prices that most low-income
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Figure 3 - Countries with % of districts achieving at least 80% DTP3 coverage, 2007.
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion
whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or
of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate
border lines for which there may not yet be full agreement. WHO 2008.All rights reserved.countries were unable to afford [17]. Additional factors
such as inadequacy of disease surveillance, inter alia, are
also contributing to the North South divide with 12 child-
hood vaccines routinely used in established market
countries and only six in most developing countries. Since
that time, the introduction of new and underused vaccines
has made and continues to make progress. By the end of
2007, 171 (of which two in part of the country) member
states had introduced hepatitis B vaccine into their routine
immunization programme compared to 31 Member States
in 1992, the year of the World Health Assembly resolution
recommending global vaccination against hepatitis B [18].
Global coverage with three doses of hepatitis B vaccine was
then estimated at 65% (Figure 4) and is as high as 88% in
the WHO Region of the Americas, in contrast to 69% in the
African Region and 30% in the South-East Asian Region.
This has to do with the lack or partial introduction of hep-
atitis B vaccination in large population countries. One
hundred and seventy eight (92%) member states intro-
duced hepatitis B vaccination by the end of 2008. However,
whereas much progress has been made with the routine use
of hepatitis B vaccine, this has taken 15 years since the
World Health Assembly recommended its universal use. A
similar time lag is unfortunately being experienced with
Haemophilus influenzae type b (Hib) vaccine, for which
global coverage remains low at 26% in 2007 (Figure 4).
WHO recommends, that in view of their demonstrated
safety and efficacy, conjugate Hib vaccines should be
included in all routine infant immunization programmes
[19]. A previous WHO recommendation encouraged vac-
cine use only in countries where burden was demonstrated
and this may have limited vaccine introduction particular-
ly in the Asian region where the burden was once debated.
One hundred and thirty five states (70%) introduced Hib
vaccination by the end of 2008 and a further nine coun-
tries are expected to introduce the vaccine before the end
of 2009. Hib vaccine uptake is highest in the Americas
(91% with three doses of Hib). This reflects, in great part,
the support from the Pan American Health Organization
(WHO Regional Office for the Americas) Revolving Fund
[20]. This pooled procurement mechanism has helped
supply nearly 40 countries with a range of affordable qual-
ity vaccines and syringes for over 30 years. Sri Lanka was
the first country in the WHO South-East Asia region to
introduce Hib vaccine as of January 2008. In 2007, a
record number of countries applied to the GAVI for Hib
vaccine introduction. Projections from GAVI applications
suggest that by the end of 2009, more than 50% of chil-
dren living in countries eligible for GAVI funding support
will have access to Hib vaccines.
These developments are accompanied by member states
increasing uptake of newly licensed vaccines against
rotavirus diarrhoea and human papillomavirus infection
and of the pneumococcal conjugate vaccine. The fast
progress in introducing new vaccines has been facilitated
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Figure 4: Global coverage estimates from selected vaccines, 1980-2007.
BCG (1 dose) , DTP (3 doses), Measles containing vaccine (1 dose), Hepatitis B (3 doses) and Hib (3 doses).
Source:WHO/UNICEF coverage estimates 1980-2007, August 2008, 193 WHO Member States.by member states’ growing recognition of the value of the
protection conferred by vaccines and immunization. Such
progress has also been made possible by the establish-
ment of global financing mechanisms, including the
GAVI, and the important role played by regional procure-
ment mechanisms, for example the Revolving Fund for
Vaccine Procurement in the Region of the Americas.
Rotavirus vaccine is now in use in 14 countries (two with
partial introduction); five additional countries are expect-
ed to have introduced the vaccine by the end of 2009 with
GAVI support (WHO/IVB database on new vaccine intro-
duction, as of 31 May 2009). This marks the first time that
the introduction of a vaccine has occurred simultaneous-
ly in both developed and developing countries.  
By the end of 2008, pneumococcal conjugate vaccine was
in universal use in 21 countries (four with partial intro-
duction). Another 17 countries have plans to introduce
the vaccine between 2009 and 2012. In March 2007,
WHO published a position paper encouraging countries
with high child mortality to consider introducing pneu-
mococcal conjugate vaccines into their national
immunization programmes (WHO/IVB database on new
vaccine introduction, as of 31 May 2009) [21]. On April
24, 2009, Rwanda became the first GAVI-eligible country
to introduce pneumococcal conjugate vaccine.
Further efforts needed and challenges
Indeed, both coverage expansion to reach the never/un-
reached with traditional Expanded Programme on
Immunization vaccines and the addition of a number of
new vaccines available by 2012 are critical elements of the
GIVS. In spite of progress, however, much remains to be
done if the full potential of immunization is to be
exploited in achieving the health-related MDGs. About
1.1 million deaths of children under the age of five could
be prevented through immunization with new vaccines
against pneumococcal disease and rotavirus diarrhoea. In
addition, vaccines against human papillomavirus infec-
tion could prevent nearly 250,000 annual deaths of
women from cervical cancer.
More vaccines will soon become available on a large scale
for use, among others, against meningococcal diseases,
Japanese encephalitis and typhoid [22-24]. In addition,
governments, multilateral agencies, foundations, and
research institutions, among others, have substantially
increased their investment in the development of new
vaccines. As a result, various new vaccines are likely to be
available for introduction in the next 10 years. These
include, in particular, vaccines against dengue, tuberculo-
sis and malaria. However, countries increasingly have to
decide which of these life-saving tools they should
finance and use on a routine basis.
The introduction of new vaccines poses challenges to the
existing logistics and cold chain requirements due to their
current presentations. In particular, the high volume of
the pre-filled glass syringe presentation of the 7-valent
pneumococcal conjugate vaccine is exceeding the central
cold chain storage capacity of some countries and the safe
use and disposal of used glass syringes and needles poses
a waste management challenge. These issues are being
addressed through assistance to countries to improve vac-
cine and waste management and through interaction with
industry to seek more suitable formulations and presen-
tations of new vaccines. Many activities are also ongoing
in the area of surveillance of diseases targeted by new vac-
cines including enhanced laboratory networks and
centres of excellence. 
WHO and its immunization partners have identified a set
of activities to accelerate the introduction of new life-sav-
ing vaccines. WHO maintains a global new and
under-utilized vaccines action plan, which provides a
platform for coordinating the activities of global partners
related to the introduction of vaccines in countries that
need them most. Decisions on implementing new and
underutilized vaccines require scientific evidence and
data, a reliable supply of affordable vaccines, which are
adapted to the country’s immunization schedule, and an
integrated disease monitoring and surveillance system.
Work has begun on the implementation of this action
plan, including the development of strategic options to
support the introduction of more expensive new vaccines
in low middle-income countries.
The GIVS provides the countries with the opportunities to
also implement other strategies for expanding the bene-
fits of vaccines to older age groups, either to complement
disease control achieved by infant immunization
(i.e. catch up vaccination of adolescents against hepatitis
B or administration of booster doses of other vaccines to
increase the duration of protection) or to target diseases
that occur in older age groups, like human papillomavirus
seasonal influenza, and typhoid. 
In setting the future agenda two other points deserve
attention. First is the need to develop integrated strategies,
whereby immunization is implemented as one element
of a comprehensive approach to disease control, be it
meningitis/pneumonia control, diarrhoeal diseases con-
trol, cancer control or epidemic/pandemic prevention
and control. Second, the delivery of routine immuniza-
tion must be seen by all as the basis and the foundation
of immunization programmes and must be given
attention and dedicated resources. Indeed, reaping the
full potential of immunization and including the full
benefit of new vaccines can only occur with increasing
overall protection and reducing coverage inequities.
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local inequities and challenges. It is also essential that one
looks at age-appropriate immunization for all antigens
separately and not only at the proportion of children fully
immunized by a certain age. Understanding the reasons
for the lack of or delayed vaccination and finding innova-
tive ways to reach the unreached and expand
immunization to include older age groups to deliver new
vaccines or booster doses is essential and operational
research is needed to this effect. In this context, one can
only applaud the multifaceted and geographic range of
research efforts undertaken under the aegis of the
Canadian International Immunization Initiative Phase 2
(CIII2) Operational research grants and reported in this
supplemental issue [25-37]. These research projects have
provided information on what needs to be better under-
stood at a local level when health workers are trying to
increase coverage in order to tailor their immunization
programming: a) perception of childhood illness and
what households see as appropriate time to vaccinate; b)
gap in decision making at household level and vaccina-
tion process; c) vaccination procedures set by health
services; d) who are those that are not completely vacci-
nated and why; e) role of religion in the decision to
vaccinate or not and how often, etc. They also provided
evidence on the impact of gender in relation to age-
appropriate immunisation. 
To be successful in the future, we must tackle the techni-
cal, logistics, political and social obstacles that are
impeding progress. At global level, we learn that evidence-
based policies and well-designed strategic direction are
critical factors in guiding the choices of countries and
their partners. Since 1974, WHO has facilitated global
consensus, commitment and cooperation among several
partners, on vaccines standards, immunization policies
and strategic direction in support of developing countries.
Internationally, WHO provides recommendations via
three main groups: (1) the Strategic Advisory Group of
Experts (SAGE); (2) the Global Advisory Committee on
Vaccine Safety (GACVS); and (3) the Expert Committee
on Biological Standardization (ECBS) [38]. 
Since 1999, SAGE for immunization gathers some of the
best world experts in the field of vaccines and immuniza-
tion and provides policy and strategic advice to WHO.
SAGE was restructured in 2005 to meet the needs of the
GIVS and now reports to the WHO Director-General,
reviews and approves all WHO policy recommendations,
including the WHO position papers on vaccines. These
are summaries of information about licensed vaccines of
public health interest which are based on an extensive
review and ranking of evidence by experts, and inputs
from interested parties and industry. They are designed to
be used by immunization and public health officials to
make decisions about the public health value and use of
specific vaccines in regions and countries. Recently SAGE
helped to clarify WHO’s position on the global use of Hib
vaccine, thus facilitating the work of the GAVI Hib vaccine
Initiative in support of country level decision-making.
Over the past couple of years, SAGE made recommenda-
tions to WHO on the use of pneumococcal conjugate,
rotavirus and typhoid vaccines, to mention a few, which
were used to develop WHO related position papers
[21,24,40].
Recommendations need to be adapted to each country.
Their aim is not to prescribe rigid immunization sched-
ules that all programmes must follow, but rather to offer
a framework which countries can adapt to existing sched-
ules and local epidemiological, economical and other
circumstances and in the context of other health priori-
ties. Supporting the establishment/strengthening of
National Immunization Technical Advisory Committees
that can convert global policy recommendations into a
national policy is one of WHO’s priorities. This is part of
the process to ensure evidence-based decision at country
level, which is particularly needed in view of the com-
plexity of the immunization programs and cost of new
vaccines [40]. 
The GACVS was established to respond promptly to vac-
cine safety issues of potential global importance. The
committee does not directly determine immunization
policies, but it does express its scientific opinion on vac-
cine safety, which could result in policy changes. The
committee evaluates questions of vaccine safety by thor-
oughly reviewing the latest developments in basic science,
epidemiology and clinical practice. All aspects of vaccine
safety are covered, whether of national or international
interest. The impartiality of the committee is essential and
explains why its mandate is distinct from that of SAGE.
The committee has on occasion found the alleged harm-
fulness of certain vaccines to be unsubstantiated, yet has
also promptly recognized, when the need has arisen, the
link between a given vaccine and adverse effects [41].
The WHO ECBS was established to set norms and stan-
dards for the manufacturing, licensing and control of
biologicals. The committee provides guidelines on vac-
cine manufacturing, quality control, product labeling,
transportation and storage, and makes recommendations
on assays and other tests of vaccine quality, safety and
immunogenicity [38]. 
Finally, the prequalification is the procedure that WHO
has established to assess the acceptability, in principle, of
vaccines for purchase by UN agencies. The pre-qualifica-
tion process was originally codified in 1989, and was
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cies, many countries now use the list of WHO
pre-qualified vaccines to select reliable and high quality
vaccines. 
Securing adequate and affordable vaccine supply as well
as long-term predictable funding for vaccines and immu-
nization is one of the top priorities of the global
community in support of the world’s poorest people. 
For 117 middle and low-income countries, the related cost
has been estimated to be $76 billion for vaccines and
delivery systems for routine immunization, mass cam-
paigns for accelerated disease control initiatives and new
vaccines introduction [43]. The need for accelerated intro-
duction of new vaccines in all high-burden countries must
be matched by adequate financial support, including sup-
port for countries with lower-middle incomes. Such
countries are not eligible for funding from the GAVI and
support for them has heretofore been insufficient or lack-
ing. As a result, these countries are starting to face
increasing financial and technical challenges in order to
maintain the same levels of access to newer technologies
as low-income countries, which benefit from financial and
technical assistance from sources such as the GAVI Fund.
Limited access to international support is resulting in
lower-middle income countries beginning to lag behind
the poorest countries in protecting their populations from
vaccine-preventable diseases using newer vaccines and
combination vaccines. The current global financial crisis
will unfortunately make the overall financing of the
immunization programmes even more challenging.
To meet the above challenges and reach the immuniza-
tion objectives already expressed in the United Nations
General Assembly special session on children (2002) and
further enunciated in the GIVS, strong disease surveil-
lance and programme monitoring systems are required.
WHO and its partners have developed a global framework
for vaccine preventable disease surveillance and immu-
nization programme monitoring [44]. This framework
combines the use of countrywide active surveillance, pas-
sive aggregate disease reporting, sentinel site surveillance,
and prospective, time-limited projects to generate the
comprehensive epidemiological data required to guide
immunization programmes. It also outlines strategies
such as ongoing monitoring of vaccine management and
vaccine safety, as well as cross-sectional programme
reviews to assess the state of programmes at the district
and health facility levels.
Continuous measurement of vaccination coverage is key
to assessing programme performance and also taking
timely corrective action. Ideally, coverage monitoring
should be based on accurate and timely reporting of
administrative data that is reported up from the most
peripheral levels to the national, regional and global lev-
els. The data should be used at the different administrative
levels for timely corrective action when the data indicate
gaps or failures in the programme. Population-based sur-
veys and data quality audits serve to validate the coverage
estimates. The WHO-UNICEF joint reporting format on
national immunization performance collects annually
information from 193 member states and has been an
important source for global monitoring of immunization
performance [45]. While in most countries, the coverage
estimates based on administrative data reported by coun-
tries are validated by surveys, in some countries wide
discrepancies between coverage estimates based on admin-
istrative data and coverage surveys still exists. Efforts are
ongoing to provide such countries with support to deter-
mine the sources of error in the administrative coverage
data and take corrective action [46,47].
As has been demonstrated by the global poliomyelitis
eradication initiative, efficient surveillance systems can be
established, even in resource-poor settings, at quite low
cost relative to the cost of the intervention itself. The
poliomyelitis surveillance network provides a structure
for rapidly detecting and responding to diseases of
national and international importance. Where appropri-
ate, this network should serve as the platform both for an
integrated disease surveillance system that provides epi-
demiological data on other communicable diseases, and
for detection and response to emerging infectious disease
threats. Funding for disease surveillance is usually disease
specific and time limited. In the presence of weak nation-
al systems, parallel systems tend to be established in order
to generate data suited to the needs of specific pro-
grammes. These uncoordinated efforts may address
short-term needs, but are unsustainable in the long term.
The global framework provides an opportunity for immu-
nization partners to coordinate their efforts to secure
sustainable funding for surveillance and programme
monitoring. 
Developments in vaccines and immunization provide us
with tremendous opportunities to impact the health of
our populations, particularly the health of poor and mar-
ginalized communities who carry the disproportionate
burden of disease. This opportunity comes with big chal-
lenges for weak health systems. GIVS provides a
framework for maximizing the benefits of vaccination,
but also creating efficiencies through an integrated and
synergistic approach to health care delivery.
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